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    Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat symptoms 
caused by rheumatoid arthritis due to their ability to inhibit prostaglandin synthesis by inhibiting cyclooxygenase 
(COX). The side effects of NSAIDs are also associated with inhibiting prostaglandin production. Consequently, their 
application is problematic. NSAID selective COX-2 inhibitors give minor gastrointestinal complications. Our study 
aims to compare nonsteroidal anti-inflammatory inhibitors of COX-1 and COX-2 regarding side effects in the 




 Non-steroidal anti-inflammatory (NSAID)s drugs are the most commonly utilized 
medicines proving their efficacy in reducing pain and inflammation. They have analgesic, anti-
inflammatory, and antipyretic efficacies, and apart from this, NSAIDs are proved to offer 
protection against various critical disorders, including cancer
1
 and heart attacks
2
 (aspirin). The 
main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX). 
COX inhibitors are classified into non-selective non-steroidal anti-inflammatory drugs (NSAIDs), 
COX-2 selective non-steroidal anti-inflammatory drugs (c2s NSAIDs), and aspirin. The 
conversion of arachidonic acid into prostaglandin is catalyzed by the cox enzyme. There are two 
known isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)
3
.Exist more than 20 
COX inhibitors, and each of them varies in the amount they can inhibit each of the isoforms. 
Prostaglandins (PGs) performed by the enzymatic activity of COX-1 are principally included in 
regulating homeostatic functions throughout the body, whereas PGs performed by COX-2 
essentially mediate pain and inflammation. Based on structural differentiation in the existing sites 
of COX-1 and COX-2, a new class of drugs has been improved that explicitly inhibits COX-2 but 
not COX-1 activity. By maintaining the synthesis of homeostatic PGs, these specific inhibitors of 
COX-2 provide the clinical advantages of nonsteroidal anti-inflammatory drugs and reduce the 
consequences of nonspecific inhibition of PG synthesis
4
.The COX-1 enzyme controls many 
cellular processes, including platelet aggregation, kidney afferent arteriole vasodilation, and 
gastric mucosa acid protection. On the other side, the COX-2 enzyme is an inducible enzyme and 
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progressed while inflammatory processes started. It is evident and present in the brain, bone, 
kidney, and female reproductive system
5
. 
 Our study aims to compare the side effects that COX-1 and COX-2 have in the 
gastrointestinal tract in patients diagnosed with rheumatoid arthritis. 
 Rheumatoid arthritis (RA) is a well-known systemic inflammatory autoimmune disease 
defined by painful, swollen joints that can seriously cause damage to physical function and quality 
of life
6
. The main purpose of treatment for RA is to reduce joint inflammation and pain, maximize 
joint function, and prevent joint destruction and deformity. Treatment regimens consist of 
combinations of pharmaceuticals, weight-bearing exercise, educating patients about the disease, 
and rest
7
. The first-line treatment of AR is to decrease pain and reduce inflammation. Medications, 
examined to be fast-acting, are nonsteroidal anti-inflammatory drugs (NSAIDs), including 
acetylsalicylate (Aspirin), naproxen, ibuprofen, etodolac, celecoxib etc.NSAIDs act by inhibiting 
cyclo-oxygenase from preventing the synthesis of prostaglandins, prostacyclin, and 
thromboxanes
8
. Common side effects are nausea, abdominal pain, ulcers, and gastrointestinal (GI) 
bleeding. These symptoms can be reduced if taken with food, antacids, proton pump inhibitors, or 




 Non-steroidal anti-inflammatory drugs (NSAIDs) hold the potential to produce 
unfavorable events through their actions on the cyclo-oxygenase (COX)-1 and COX-2 enzymes, 
including gastrointestinal ulcers and bleeding (COX-1), cardiovascular (CV) events  like 
myocardial infarction and stroke (COX-2 > COX-1) hypertension and kidney injury (COX-1 and 
COX-2)
10
. Selective cyclooxygenase-2 inhibitors (coxibs) look to be correlated with a lower 
incidence of GI adverse reactions when compared to classical NSAIDs. Certainly, some clinical 
trial has confirmed fewer GI complications in coxib group compared to classical NSAIDs
11
. There 
have been done several studies of the pathogenesis of NSAID-induced gastrointestinal illness. 
NSAIDs are able to inhibit prostaglandin-endoperoxide synthase 1 (PTGS1 or COX-1) and COX-
2, which have been thought to mediate gastrointestinal trouble
12,13.14
. NSAID-induced reductions 
in mucosal levels of prostaglandins correlate with gastric and small bowel damage
15,16,17
, which 
can be attenuated by the administration of exogenous prostaglandins
18
. COX-2 is not 
constitutively manifested in the gastrointestinal tract COX-2 selective inhibitors are perceived as 
safer than conventional NSAIDs
19
. Suggested mechanisms of damage to the gastrointestinal tract 
include prostaglandin mediated enhanced gastric acid secretion, reduced mucus and bicarbonate 
secretion, diminished cell proliferation and mucosal blood flow
20
. NSAIDs can usually cause 




 Two fundamental strategies have been improved to prevent the increase of gastrointestinal 
mucosal injury in patients using NSAID: co-therapy with a gastro-protective agent or replacement 
of a common NSAID with a COX-2 inhibitor. The gastro-protective agents may include a 
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histamine-2 receptor antagonist (H2RA), misoprostol, or a proton-pump inhibitor (PPI). 
Systematic reviews have shown that these strategies are variably effective to reduce the risk of 





 This is a retrospective study that aims to assess and compare the gastrointestinal 
complications of COX-1 and COX-2 in patients diagnosed with rheumatoid arthritis. There are 
250 patients with AR diagnosis evaluated in the hospital at QSUNT during 2018-2019. Two 
hundred patients are treated with naproxen 500 mg / 1 time per day and omeprazole 20 mg / 1 time 
per day; 50 patients are treated with celecoxib 200 mg / 1 per day. For all patients, the duration 
and treatment were eight weeks. We investigated gastrointestinal side effects like abdominal pain, 




 We evaluated 250 patients (the year 2019) with rheumatoid arthritis diagnose who have 
been used NSAIDs COX-1 and COX-2 and understand what side effects and complications they 
have after using for eight weeks naproxen 500mg and omeprazole 20 mg per day (in this group, 
there are 200 patients) in comparison with patients (n=50) who have been treated with celecoxib 




Patients treated with naproxen 500mg 
+ omeprazole 20 mg for 8 weeks 
(n=200) 
Patients treated with 
celecoxib 200mg 










Dyspepsia 40 (20.0) 2 (4.0) 42 (16.8) 0.007 
Vomiting 20 (10.0) 1 (2.0) 21 (8.4) 0.068 
Heartburning 30 (15.0) 4 (2.0) 31 (12.4) 0.013 
Gastric ulcers 
(Fibrogastroscopy) 18 (9.0) 1 (2.0) 19 (7.6) 0.095 
 
Tab. 1 explains a version of the results obtained from the clinical signs that rheumatoid arthritis 
patients have shown during treatment  with naproxen 500mg + omeprazole 20 mg for 8 weeks and 
patients treated with celecoxib 200mg in a period of 8 weeks. 
 
 Forty-two patients (16.8%) had dyspepsia, of which forty patients were treated with 
naproxen + omeprazole and two patients treated with celecoxib (p = 0.007), and the conclusion is 
statistically significant. Twenty-one patients (8.4%) had vomiting; from them, only one patient 
was treated with the celecoxib (p = 0.068). Thirty-one patients (12.4%) complained of 
heartburning; 30 patients were treated with naproxen + omeprazole and one patient with celecoxib 
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(p = 0.013). The result is statistically significant. Gastric ulcer was confirmed endoscopically in 19 
(7.6%) cases, where 18 treated with naproxen + omeprazole, and one was treated with celecoxib 








Fig. 1 shows us a simple graphical illustration of how the side effects are manifested in patients 
treatment  with naproxen 500mg + omeprazole 20 mg and in patients treated with celecoxib 
200mg for a period of 8 weeks. 
 
 Discussion 
 Non-steroidal anti-inflammatory drugs (NSAIDs) are generally prescribed and 
recommended to treat pain in arthritis rheumatoid. While measured to have a good effect on pain 
in arthritis rheumatoid, NSAIDs have been connected with wide-ranging adverse events affecting 
the gastrointestinal. Our study has a significant meaning in helping with therapeutic decisions on 
the appropriate choice of medications for patients with AR by having the minimum side effect in 
the gastrointestinal tract. Gastrointestinal complications are found with all NSAIDs, but recent 
studies have found that gastric events may be reduced by taking the suitable NSAID, which 
probably is COX-2 (celecoxib). However, celecoxib presented significant reductions in the risk for 
several outcomes compared with other commonly used NSAIDs (naproxen 500mg + omeprazole 
20 mg)
22
.  Rheumatoid arthritis is a chronic disease that has no remedy. Rheumatoid arthritis is a 
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chronic disease that has no remedy. However, the drugs used to treat rheumatoid arthritis also 
have potential side effects, which often are not well-tolerated. Still, future approaches are focus on 
improving medical therapies that offer a better quality of life. The ideal NSAID as a medical 
treatment is more selective for COX-2 than COX-1.  
 Strategies to reduce the risk for damage to the gastrointestinal tract have introduced the 
transition to other types of drugs; lower dose systemic NSAIDs, and topical NSAIDs. In addition, 
there are other strategies include the joining of prostaglandin analogs, H2 receptor antagonists, or 
proton pump inhibitors as concomitant therapies. Immediate diagnosis and intervention are 
fundamental for the prevention of serious damage and loss of essential bodily functions
23
. 
Moreover, early referral to a specialist can improve to guarantee better treatment outcomes. 
Traditional treatment modalities have been optimized, and new ones have been produced. 
 
 Conclusion 
 COX-2 selective, present fewer gastrointestinal side effects than NSAIDs (COX-1) 
associated with PPIs. It is essential to underline that COX-2 are more expensive. Physicians need 
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